Busy Week For Japanese Firm Otsuka: Justice Dept. Settlement For Off-Label Abilify Marketing And New Partnership With MethylGene
This article was originally published in PharmAsia News
Executive Summary
Abilify developer Otsuka Pharmaceutical settled with the U.S. Department of Justice over charges the company illegally marketed the atypical antipsychotic off-label for pediatric and elderly populations in the U.S. from 2002 through 2005